
Leuko
Leuko
Claim
Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in Show MoreLeuko is developing the first non-invasive white blood cell device. White blood cell assessment is a Show More
Alpha Score
$ 10.70 M
Alpha Score
54.7
Predictions
Overview
Team
Financials
- Partnerships
Relationships
Locations
Competitors
Comparison
News
Product
Regulatory
Clinical
Patent
Publications
Notes
0and0